Molecular markers expression in prostate cancers: association with clinical and morphological features of disease

Introduction. Prostate cancers belong to the high-spread tumors among men. Objectives: The purpose of the study was to investigate Brn-3a, AR, ERa expression in prostate cancer tissues in association with AKT/mTOR signaling pathway activation, cancer invasion and grade. Materials and methods: 50 patients with locally advanced cancer of the prostate were included in the study. Expression of Brn-3a, AR, ERa, components of AKT/m-TOR signaling pathway was determined by RT-PCR. Results. Overexpression of Brn-3a was found in prostate cancer tissues, which was accompanied by high level of ERa mRNA. Activation of AKT/m-TOR signaling pathway was revealed in cancers. It was noted that the invasion of tumor was associated with high expression of ER, AR, PTEN as well as decreased mRNA level of m-TOR. The low activity of AKT/m-TOR signaling pathway was revealed in least-differentiated tumors. Decrease of AKT, GSK-3b expression and increase of 4E-BP1 happened in least-differentiated tumors compared to well-differentiated tumors (Gleason score 6-7). The altered protein kinase expression was associated with overexpression of PTEN. Conclusion. These data, reflecting the biological features of cancers, are the molecular pattern of prostate tumors progression.

транскрипционный фактор Brn-3a, рак предстательной железы, AR, ER, сигнальный путь AKT/m-TOR, кастрационно-рефрактерная форма, коэффициент Глисона, инвазия, transcription factor Brn-3a, prostate cancer, AR, ER, AKT/m-TOR signaling pathway, castrate-refractory cancer, Gleason score, invasion

1. Amiya Y, Yamada Y, Sugiura M, Sasaki M, Shima T, Suzuki N, Nakatsu H, Murakami S, Shimazaki J. Treatment of locally advanced prostate cancer (Stage T3). Jpn J Clin Oncol. 2017 Jan 17. doi: 10.1093/jjco/hyw186.

2. Маркова АС, Поликарпова СБ, Камолов БШ, Гриднева ЯВ, Калинин СА, Петерс МВ, Матвеев ВБ. Факторы прогноза общей выживаемости больных метастатическим кастрационно-резистентным раком предстательной железы. Онкоурология. 2015;11(2):77-84.

3. D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004 Nov;172(5 Pt 2):42-46.

4. Makarov DV1, Partin AW. Prostate-Cancer Risk Stratification via Early PSA Testing. Rev Urol. 2007;9(2):91-92.

5. Strand SH, Hoyer S, Lynnerup AS, Haldrup C, Storebjerg TM, Borre M, Orntoft TF, Sorensen KD.High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. Clin Epigenetics. 2015;7:111. doi: 10.1186/s13148-015-0146-5.

6. Niedworok C1, Tschirdewahn S1, Reis H2, Lehmann N3, Szucs M4, Nyirаdy P4, Romics I4, Rubben H1, Szarvas T5,6.Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival. Pathol Oncol Res. 2016. doi: 10.1007/s12253-016-0171-5.

7. Budhram-Mahadeo V, Fujita1 R, Bitsi1 S, Sicard P, HeadsR. Co-expression of POU4F2/Brn-3b with p53 may be important for controlling expression of pro-apoptotic genes in cardiomyocytes following ischaemic/hypoxic insults. Cell Death and Disease. 2014;5:1503. doi:10.1038/cddis.2014.452

8. Diss JK, Faulkes DJ, Walker MM, Patel A, Foster CS, Budhram-Mahadeo V, Djamgoz MB, Latchman DS, Berwick DC. A simple technique for the prediction of interacting proteins reveals a direct Brn-3a-androgen receptor interaction. J. Biol. Chem. 2010;285:15286-15295.

9. Berwick DC, Diss JK, Budhram-Mahadeo VS, Latchman DS. A simple technique for the prediction of interacting proteins reveals a direct Brn-3a-androgen receptor interaction. J Biol Chem. 2010;285(20):15286-15295. doi: 10.1074/jbc.M109.071456. Epub 2010 Mar 12.

10. Stoica J, Franke FT, Wellstein A, Szubaiko F, List H-J, Reiter R, Morgan E, Martin MB, Stoica A. Estradiol Rapidly Activates Akt via the ErbB2 Signaling Pathway. Molecular Endocrinology. 2003;17:818-830.

11. Vamesu S. Angiogenesis and ER/PR status in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom. J. Morphol. Embryol. 2007;48:25-31.

12. Ahmad N, Kumar R. Steroid hormone receptors in cancer development: A target for cancer therapeutics. Cancer Letters. 2011;300:1-9.

13. Wang Y. Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum. Mol. Genet. 2010;19:4319-4329.

14. Spirina LV, Usynin YA, Kondakova IV, Yurmazov ZA, Slonimskaya EM, Kolegova ES. The AKT-mTOR Signalling Pathway in Kidney Cancer Tissues. AIP Conf Proc. 2015;1688: 080004-1-5.

15. Спирина ЛВ, Усынин ЕА, Кондакова ИВ, Юрмазов ЗА, Слонимская ЕМ. Влияние таргетной терапии на содержание транскрипционных, ростовых факторов, протеинкиназы TOR и активности внутриклеточных протеиназ у больных диссеминированным раком почки. Бюллетень экспериментальной биологии и медицины. 2015;60(6):768-772.

16. Spirina LV, Usynin EA, Kondakova IV, Yurmazov ZA, Slonimskaya EM. Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. Bull Exp Biol Med. 2016. 60(6):798-801.

17. Горбунов АК, Спирина ЛВ, Усынин ЕА, Слонимская ЕМ, Кондакова ИВ. Роль транскрипционного фактора в развитии рака предстательной железы, связь с особенностями гормональной рецепции и уровнем активации АКТ/m-TOR-сигнального пути. Успехи молекулярной онкологии. 2016;3:54.

18. Zellweger T1, Gunther S, Zlobec I, Savic S, Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E, Rufenacht H, Bachmann A, Gasser TC, Mihatsch MJ, Bubendorf L. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer. 2009;124(9):2116-23.

19. Dunsmuir WD1, Gillett CE, Meyer LC, Young MP, Corbishley C, Eeles RA, Kirby RS. Molecular markers for predicting prostate cancer stage and survival. BJU Int. 2000 Nov;86(7):869-78.